Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Predicting the future of anti-tumor necrosis factor therapy

Cornelis L Verweij

Author Affiliations

Division of Inflammatory Disease Profiling, Department of Pathology and Rheumatology, VU University Medical Center, P.O. Box 7057, 1007MB Amsterdam, The Netherlands

Arthritis Research & Therapy 2009, 11:115  doi:10.1186/ar2724


See related research article by Hueber et al., http://arthritis-research.com/content/11/3/R76

Published: 22 June 2009

Abstract

Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonresponders'. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research & Therapy, Hueber and colleagues become the first to present a multi-parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately, this finding may contribute to a personalized form of medicine, whereby a specific therapy will be applied that is best suited to an individual patient.